Shilpa Medicare Ltd (SHILPAMED) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue Growth
Management consistently highlighted that the Biologics and Formulations segments will primarily drive overall growth, while the API division is projected to maintain a steady upward trajectory supported by volume scale-ups. [Status: Reaffirmed expectations for stable API expansion and healthy formulations growth for the fiscal year ending Mar'27, with licensing income anticipated to remain stable at around INR 150 crores annually across the Dec'25 and Mar'26 quarters]
3 more themes on the ELITE plan.